Quality by Design Approach for the Development and Validation of Glipizide, an Antidiabetic Drug, by RP-UPLC with Application to Formulated Forms and Urine. (27th February 2013)

• Record Type: Journal Article
• Authors: Xavier, Cijo M.; Basavaiah, Kanakapura; Vinay, K. B.; Swamy, N.
• Other Names: Bruzzoniti M. C. Academic Editor.; Hassan M. Academic Editor.; Suarez A. I. Academic Editor.
• Is Part Of: ISRN chromatography. Volume 2013(2013)
• Publication Date: 2013-02-27
• Subjects: Chromatographic analysis -- Periodicals; Chromatographic analysis; Electronic journals; Periodicals; Electronic journals; 543.8
• DOI: 10.1155/2013/738397
• Languages: English
• ISSNs: 2090-8636

Abstract

Abstract : Quality by design (QbD) refers to the achievement of certain predictable quality with desired and predetermined specifications. The objective of this study was to develop and demonstrate an integrated multivariate approach to develop and quantify the constituent concentrations of glipizide (GPZ) drug in its pure and tablet forms. The method was developed using Zorbax Extend C-18 (50 mm × 4.6 mm × 1.8 μ m) column with mobile phase consisting of a mixture of phosphate buffer of pH 3.5 and acetonitrile (60 : 40 v/v). The method fulfilled validation criteria and was shown to be sensitive, with limits of detection (LOD) and quantitation (LOQ) of 0.001 and 0.005 μ g mL −1, respectively. The percentage relative standard deviations for robustness and ruggedness were observed within the range of 0.1 and 0.99. The calibration graph was linear in the range of 0.005–300 μ g mL −1 . The applicability of the method was shown by the analysis of formulated drug and spiked urine samples. The proposed method can be used for routine analysis in quality control laboratories for its bulk and formulated product, and this is the first UPLC method reported for the assay of GPZ in bulk, formulated form and urine.